Instead, a number of features argue for the infiltrating inflammatory immune cells being the main driver of lesion formation in MS:
cates that the pathogenic process involved in the onset of MS plaques is perivascular, evolving from inflammatory immune cell infiltration from the periphery through a leaking BBB. In actively induced experimental autoimmune encephalomyelitis (EAE), the model for MS, perivascular inflammatory infiltration leading to demyelination is massive, and adoptive transfer of activated myelin-specific T cells is sufficient to induce disease in naïve mice; most importantly, activated T cells that do not recognize a brain antigen, and thereby do not home to the CNS, are incapable of inducing disease. Perivascular infiltration of myelin-specific T cells leads to the recruitment of monocytes and a recent study suggested that recruitment of peripheral macrophages, which are mostly responsible for myelin destruction in active lesions, could be related to the deposition of fibrinogen, a central blood coagulation protein, into the CNS after moderate damage of the BBB by the perivascular T-cell infiltrates. 4 In addition to activation of antigen-presenting cells, including dendritic cells, and ensuing T-cell recruitment to the CNS, fibrinogen has also been implicated in the activation of microglia, and in EAE, the initiation of neuroinflammation is strongly associated with the attraction of pathogenic T cells toward perivascular Rather than playing a crucial role on the formation of lesions, astrocytes could limit immunopathogenesis.
As recently demonstrated, reactive astrocytes under inflammatory conditions induce the formation of tight junction at the glia limitans, thereby controlling the trafficking in the CNS parenchyma of inflammatory T cells involved in lesion formation. 8 Additional studies attribute a possible anti-inflammatory role to astrocytes that is not related to their role at the BBB. Thus, selective knockdown in astrocytes of the immunomodulatory transcription factor, aryl hydrocarbon receptor, resulted in increased EAE severity associated with an increase in infiltrating monocytes and neurotoxicity. 9 A similar disease worsening was observed when reactive astrocytes were specifically depleted in EAE mice in acute disease or at non-progressive phases of chronic EAE. 9 However, there is little doubt that astrocyte activation plays a pivotal role in the progressive stages of the disease, where infiltration of peripheral immune cells is no longer the main player in lesion formation. Indeed, as disease progresses, inflammatory infiltration in the lesions decreases, but there is clear astroglial activation. Astrocytes are a heterogeneous population and two different types of reactive astrocytes induced by neuroinflammation, A1 and A2, were recently defined, with A1 astrocytes being highly neurotoxic. 10 Such activated astrocytes are found in areas of myelin breakdown and are a source of cytotoxic factors, inhibiting remyelination and axonal regeneration, and, in contrast to what is observed in acute EAE stages, their depletion at the chronic phase of EAE results in disease amelioration. 9
One of the main objections to attributing a major role in lesion formation to the peripheral leukocyte infiltrates has been the fact that anti-inflammatory disease-modifying drugs, despite their ability to slow down the appearance of new lesions, do not generally stop disease progression. However, it must be taken into consideration that by the time clinical signs appear and patients are treated, MS lesions might have developed to a point where the involvement of innate immune cells in the CNS, astrocytes and microglia, is too far advanced, leading to CNSinherent inflammation associated with neurodegeneration, which cannot be stopped by drugs that target lymphocytes. Only the possibility to detect individuals at risk for MS and to anticipate anti-inflammatory treatment and/or identify therapeutic windows of opportunity will permit to fully appreciate the real benefit of inhibiting leukocyte infiltration in the CNS and therefore the ensuing therapeutic need to target astroglial activation to prevent further tissue degeneration.
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The author(s) received no financial support for the research, authorship, and/or publication of this article. At least three of their functions are relevant for the role of astrocytes in MS lesions. First, astrocytes can limit the recruitment of inflammatory cells to the CNS by modulating blood-brain barrier (BBB) integrity and stability, 5 and also by forming an inducible barrier with their foot processes at the glia limitans. 6,7 Second, astrocytes control lesion-promoting functions in other cells. For example, astrocytes produce molecules that modulate T-cell function such as interleukin (IL)-27, which limits effector T-cell responses directly and indirectly. 8-10 Astrocyte products can also promote neurotoxic activities in microglia, and recruit pro-inflammatory monocytes which contribute to disease pathology and lesion formation. 2, [11] [12] [13] Third, astrocytes themselves can display neurotoxic activity, the factors controlling it and the specific neurotoxic astrocyte populations involved are just starting to be identified. 14,15 Based on these and other functions, astrocytes are likely to participate in the formation and evolution of MS lesions.
Indeed, as suggested by Pitt and Ponath, some efficacious disease-modifying therapies (DMTs) are known to act on astrocytes. 16 However, as mentioned by Kerlero de Rosbo, it has to be kept in mind that other DMTs whose mechanisms of action do not involve the direct modulation of astrocyte function are also highly efficacious, highlighting the crucial role of other cell types such as T cells, microglia and monocytes in lesion pathology.
While considering the contribution of astrocytes to MS pathology, it should also be kept in mind that multiple astrocyte populations have been identified based on phenotype and function. However, their specific roles in MS pathology are still unknown. Thus, it is possible that specific astrocyte populations may promote or limit lesion development; these populations have yet to be clearly defined to establish whether they represent different lineages or activation/polarization states of astrocytes and also to determine whether they may be differentially targeted with specific therapeutics. In addition, astrocytes also play an important role in the neurodegeneration associated to MS progression. [17] [18] [19] Thus, it is important to identify specific astrocyte populations and mechanisms relevant to different aspects of MS pathogenesis (e.g. lesion formation versus brain atrophy), to define mechanisms of disease pathogenesis and develop new therapies targeting astrocytes and other CNSresident cells.
